Abstract

Although, life expectancy of metastatic breast cancer has improved over the last 20 years, it still remains a significant cause of morbidity and mortality in women. New drugs that were developed in recent years have provided significant survival benefits in the treatment of hormone receptor positive and/or HER2-positive breast cancer. Whether in combination or single-agent therapy, no significant improvement were obtained with the known cytotoxic agents in terms of survival of metastatic triple negative breast cancer. This review has focused on the current treatment approaches and the trials seeking challenging treatment options for metastatic breast cancer.